NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded the stock of BioMérieux, following its announcement two days ago that it will acquire BioFire Diagnostics.

The investment bank upgraded the French in vitro diagnostic firm to Overweight from Neutral, and increased the price target on its stock to €86 ($113.20) from €71.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.